OncoSystem Directory
Explore organizations in the global Oncology ecosystem
724 organization(s) found
Immatics
Since its foundation, Immatics has been relentlessly focused on building its scientific approach from the ground up to develop and deliver novel PRAME immunotherapies for patients with cancer. Today, Immatics is the global leader in the precision targeting of PRAME, a target expressed in more than 50 cancers, and has the broadest PRAME franchise with the most PRAME indications and modalities.
Cell therapies and biologics (bispecifics) targeting PRAME for solid tumors
Tuebingen, Germany
WebsiteImmunityBio
ImmunityBio is on a Mission: To continuously pursue new therapies that kill disease, not the immune system
Biologics and NK Cell Therapy against Blood Cancers and Solid Tumors San Diego, CA, United States WebsiteImmunity for Health
A catalyst for public-private partnerships in vaccine related research and business.
WebsiteImmunocore
We want to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.
TCR bispecific (ImmTAC) cancer immunotherapies Abingdon, United Kingdom WebsiteImmunoneering
Powerful Science Engineered to Disrupt Cancer, Not Life For decades, most cancer treatments have used continuous inhibition, applying constant pressure to block tumor growth. While this can shrink tumors quickly, it gives cancer time to adapt and develop resistance. At Immuneering, we recognized the problem: predictable therapeutic pressure allows cancer to evolve. Our scientists developed Deep Cyclic Inhibitors, a new class of medicines designed to pulse faster than cancer�s adaptive mechanisms. This rhythmic approach disrupts the tumor�s ability to resist treatment while allowing healthy cells to recover between doses. The result is more durable tumor control and improved tolerability for patients.
Small-molecule MEK inhibitor, Atebimetinib (IMM-1-104), for solid tumors including pancreatic cancer Cambridge, MA, United States WebsiteImmuto Scientific
At Immuto Scientific, we are bridging the gap between biology and engineering to explore revolutionary new therapies for oncology. Founded by a pair of engineers, our approach is rooted in the belief that true breakthroughs come from building what doesn’t yet exist. We use radical-based protein labeling to unlock structural insights on the omic scale, challenging the status quo and transforming drug discovery.
Biologics for Oncology Madison, WI, United States WebsiteIMS (International Myeloma Society)
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
Myeloma Education, Training and Research Support Boston, MA, United States WebsiteINCA (Instituto Nacional de Câncer)
INCA is the body of the Ministry of Health responsible for the development and coordination of integrated actions in the prevention and control of cancer in Brazil. Those actions include hospital care provided directly and free of charge to cancer patients within Brazil's Unified Public Health System (SUS), and interventions in other strategic areas, such as prevention and early detection, training, research and epidemiological information. The Institute coordinates several national programs on cancer control and is equipped with the most modern public diagnostic imaging facility in Latin America.
Cancer Control, Public Health and Epidemiology Rio de Janeiro, RJ, Brazil WebsiteINCa (l'Institut national du cancer)
In French: "L'Institut national du cancer (INCa) a pour ambition de jouer un rôle d’accélérateur de progrès, en apportant une vision intégrée de l’ensemble des dimensions sanitaire, scientifique, sociale, économique liées aux pathologies cancéreuses ainsi que des différents champs d’intervention (prévention, dépistage, soins, recherche). Ceci, au service des personnes malades, de leurs proches, des usagers du système de santé, de la population générale, des professionnels de santé, des chercheurs et des décideurs."
Public Health & Outreach in Oncology Boulogne-Billancourt, France WebsiteINCan (Instituto Nacional de Cancerología)
In Spanish: "El Instituto Nacional de Cancerología es un organismo descentralizado de tercer nivel, dependiente de la Secretaría de Salud; que brinda atención médica especializada a enfermos oncológicos siendo además un centro de referencia y órgano rector del cáncer en México. Dirige sus acciones a la atención de pacientes no derechohabientes de la seguridad social, provenientes de todo el país y ha sido política institucional, el otorgar servicios con eficiencia, calidad y calidez, con enfoque multidisciplinario en proceso diagnóstico, tratamiento, rehabilitación y seguimiento. Aunado a las funciones asistenciales como centro de enseñanza médica e investigación."
Mexico City, Mexico WebsiteINC - Colombia (Instituto Nacional de Cancerología)
The National Cancer Institute (nstituto Nacional de Cancerología [INC], in Spanish) is the only State Entity at the national level, dedicated exclusively to the teaching, prevention, diagnosis, treatment, rehabilitation and intervention of cancer.
Bogotá, Colombia WebsiteIncyclix Bio
Incyclix Bio is advancing next-generation precision treatments to regain control of the cell cycle where aberrant proliferation is a fundamental driver of many cancers. We believe the CDK family is a rich source of of novel cancer targets worthy of drug development. Our team is applying its unsurpassed expertise and deep knowledge of CDK inhibitors to bring hope to people with advanced and resistant cancers.ost cancer treatments have used continuous inhibition, applying constant pressure to block tumor growth. While this can shrink tumors quickly, it gives cancer time to adapt and develop resistance.
Small-molecule inhibitors of CDK to regain cell-cycle control in Oncology Durham, NC, United States WebsiteIncyte
Incyte is a Biopharmaceutical Company on a Mission to Solve On.
Hematology & Oncology,
Inflammation & Autoimmunity Wilmington, DE, United States WebsiteIndian Society of Hematology & Blood Transfusion
The Indian Society of Haematology and Blood Transfusion (ISHBT) is a non-governmental, not-for-profit professional membership organization established in 1959. The Society is dedicated to promoting excellence in patient care, research, and education in clinical and laboratory haematology. With a strong network of over 2,400 life members, ISHBT serves as a dynamic and inclusive platform for haematologists across India and beyond. It actively fosters academic advancement through its Annual National Conference, peripheral Continuing Medical Education (CME) programs, workshops, symposia, regular newsletters, and national scientific meetings that bring together leading experts and trainees from around the globe. ISHBT conducts quizzes for undergraduate, postgraduate, and postdoctoral students to foster interest in the field of haematology. The Society also awards various prizes, research grants, and medals to encourage academic excellence and stimulate research among young scholars.
Hematology & Hemato-Oncology Anandapur, Adarsha Nagar, Kolkata, West Bengal, India WebsiteINEN (Instituto Nacional de Enfermedades Neoplásicas)
In Spanish: “MISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como misión: "Proteger, promover, prevenir y garantizar la atención integral del paciente oncológico, dando prioridad a las personas de escasos recursos económicos; así como, controlar, técnica y administrativamente, a nivel nacional los servicios de salud de las enfermedades neoplásicas y realizar las actividades de investigación y docencia propias del Instituto”. VISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como visión: “Perú libre de cáncer avanzado a través de nuestro liderazgo en políticas y acciones de excelencia que promuevan el acceso universal y equitativo a la prevención y control del cáncer”.”
Surquillo (Lima), Peru WebsiteInFocus Therapeutics
We have a novel discovery platform to identify differentiated RNA-targeting small molecules – faster.
RNA-targeting small-molecule drugs for Oncology and Neurology Cambridge, MA, United States WebsiteInnate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: antibody Drug Conjugates (ADC), monoclonal antibodies (mAbs) and multi-specific NK Cell Engagers through its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform.
Marseille, France WebsiteInnovent Biologics
Innovent Biologics is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. Through our hallmark integrated approach, state-of-the-art manufacturing facilities and strategic collaborations, we are involved in every stage of a drug's lifecycle, from discovery to development to commercialization, allowing us to build robust pipelines for innovative drugs that treat cancer and other major diseases.
Drug Discovery & Development across modalities for treatment of solid tumors, blood cancers and other diseases Innovent Biologics, China WebsiteInstitut Curie
Made up of an internationally renowned Research Center and a cutting-edge Hospital Group, Institut Curie, the first French cancer center, treats all cancers, even the most rare forms.
Cancer Care & Research Paris, France Website